Changeflow GovPing Healthcare & Life Sciences FDA Grand Rounds: Anti-biofilm Technologies for...
Routine Notice Added Final

FDA Grand Rounds: Anti-biofilm Technologies for Medical Device Safety Webinar

Favicon for www.fda.gov FDA Recent Drug Approvals
Published
Detected
Email

Summary

The FDA Grand Rounds webinar, presented on May 29, 2025, by Dr. Jayaleka J. Amarasinghe of the Winchester Engineering and Analytical Center, explores two innovative anti-biofilm technologies for medical device surfaces: photothermal ablation using gold nanorod coatings and electrical stimulation to disrupt biofilm formation. The presentation addresses the challenge of biofilm resistance to conventional antimicrobials and highlights novel approaches being evaluated at WEAC/FDA to enhance medical device safety. This is an informational scientific presentation covering regulated product areas including biologics, drugs, and medical devices.

“Biofilms are communities of microorganisms encased in extracellular polymeric substances that adhere to surfaces, such as medical devices, contributing to chronic infections.”

FDA , verbatim from source
Published by FDA on fda.gov . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors FDA Recent Drug Approvals for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 10 changes logged to date.

What changed

The FDA Grand Rounds webinar presents research on two emerging anti-biofilm technologies being evaluated at the Winchester Engineering and Analytical Center: photothermal ablation using gold nanorod coatings and electrical stimulation for disrupting biofilm formation. Biofilms are described as communities of microorganisms encased in extracellular polymeric substances that adhere to medical device surfaces, contributing to chronic infections due to their resistance to conventional antimicrobials.

Manufacturers of medical devices, particularly those with surfaces prone to microbial colonization, should monitor FDA research in this area as these technologies may inform future regulatory expectations for device surface safety. The presentation represents FDA's ongoing scientific evaluation efforts rather than formal guidance or new regulatory requirements.

Archived snapshot

Apr 27, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

More Meetings,
Conferences, and
Workshops

On This Page

Date: May 29, 2025 Time: 12:00 p.m.
- 1:00 p.m.
ET

Webcast Recording

Speaker

Jayaleka J. Amarasinghe, Ph.D.
Microbiologist
Winchester Engineering and Analytical Center (WEAC)
Office of Specialty Laboratories & Enforcement Support (OSLES)
Office of Chief Scientist (OCS)
Office of the Commissioner (OC)

About the Speaker

Dr. Jayaleka Amarasinghe is a microbiologist at the Winchester Engineering and Analytical Center (WEAC), within Office of Specialty Laboratories & Enforcement Support (OSLES), the Office of the Chief Scientist (OCS), in Winchester, Massachusetts. Since joining the FDA in 2014, she has led pioneering research on characterization of biofilms associated with medical device surfaces, driving efforts to develop innovative, antimicrobial-free strategies aimed at enhancing medical device safety. Dr. Amarasinghe earned her undergraduate degree in Biology from Bay Path University in Longmeadow, Massachusetts, and her Ph.D. in Oral Biology from the University at Buffalo, State University of New York. She also completed a postdoctoral fellowship in Infectious Diseases at the New York State Department of Health. Her work has been crucial in advancing novel approaches to anti-biofilm technologies for medical devices.

About the Presentation

Biofilms are communities of microorganisms encased in extracellular polymeric substances that adhere to surfaces, such as medical devices, contributing to chronic infections. Their resistance to conventional antimicrobials makes biofilms particularly difficult to eradicate, highlighting the urgent need for novel approaches. This presentation explores two innovative technologies evaluated at WEAC/FDA to address biofilms on medical device surfaces: photothermal ablation using gold nanorod coatings and electrical stimulation aimed at disrupting biofilm formation.

  • ## Content current as of:

04/27/2026

  • Regulated Product(s)

    • Biologics
    • Drugs
    • Medical Devices

Get daily alerts for FDA Recent Drug Approvals

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from FDA.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
FDA
Published
May 29th, 2025
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Medical device makers Clinical investigators Healthcare providers
Industry sector
3345 Medical Device Manufacturing
Activity scope
Biofilm research Medical device safety Antimicrobial technologies
Geographic scope
United States US

Taxonomy

Primary area
Medical Devices
Operational domain
Clinical Operations
Compliance frameworks
GxP
Topics
Pharmaceuticals Public Health

Get alerts for this source

We'll email you when FDA Recent Drug Approvals publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!